Hiring is back for 2027: BD, Business Analysts and PIs top the Life Sciences Recruitment Agenda

4 Minutes

I've just got back from BIO-Europe 2026 in Cologne, and one message came through in almost e...

I've just got back from BIO-Europe 2026 in Cologne, and one message came through in almost every conversation I had: life sciences hiring is back on the agenda for 2027. Most of the CDMOs, CROs and biotechs I spoke to are planning to grow from Q1, and they already know which roles they need.

Three came up again and again: business development, business analysts and principal investigators (PIs). Here's what I heard, what's driving it, and what it means for companies planning their commercial hiring next year.




My three biggest takeaways from BIO-Europe

1. Growth plans start in Q1. After a cautious couple of years, most companies I met are planning to add headcount early in 2027 rather than waiting to see how the year unfolds.

2. Three roles dominate. BD, Business Analysts and PIs were the roles mentioned most, across CDMOs, CROs and biotech.

3. Demand is outpacing supply. There aren't enough of the right people to go round, and companies told me they're willing to pay above market to secure them.




The trends behind the 2027 hiring demand

Partnering and licensing: Asian and Indian players are moving into Europe

One of the clearest themes was Asian and Indian companies acquiring European entities. The aim is to gain local infrastructure and products that are already approved. We've seen this play out for a few years now, from Gland Pharma's acquisition of French CDMO Cenexi to Granules India's acquisition of Swiss CDMO Senn Chemicals. Once they've bought them, they need people to sell them, so they're building local BD teams from scratch. That creates a wave of demand for BD talent who know European pharmaceutical markets inside out, and for senior leaders to run those teams.

Investment and funding: sentiment is more positive

The mood around funding has improved, and growing dealmaking confidence was a theme going into the event. Companies that have secured investment are now adding Business Analysts across Europe and the US. Investors and leadership teams want commercial decisions backed by data, and analysts are the people who make that possible.

Australia is emerging for early-phase work

Australia is getting a lot of attention in the CRO and CRDMO space for early-phase clinical work. Sponsors are drawn by fast trial start-up and strong regulatory credibility, plus the government's R&D Tax Incentive. That's driving demand for PI hires there, and in parts of Europe too, as providers build capacity to compete.




What it means for the talent you'll need to hire

Business development: you need true hunters

Start-ups and expanding players don't need account managers. They need hunters who can open doors, with local market knowledge they can use from day one. Many companies told me they'll pay a premium to get the right person in quickly, because every month without that hire is lost pipeline. For the most senior BD and commercial leadership roles, a board and executive search approach is often the fastest route, while contract and interim support can cover the gap while you hire permanently.

Business Analysts: now a core hire, not a nice-to-have

As teams scale, someone has to turn market and pipeline data into commercial strategy. That used to be a role companies added later. Now it's becoming one of the first hires funded biotech and service businesses make, which means competition for experienced analysts is rising fast.

Principal investigators: plan well ahead

The PI talent pool is small and competition for it is global. CROs and CRDMOs that wait until a study is confirmed to start looking will struggle, especially in emerging regions like Australia. The companies that get this right are mapping the market and starting conversations months before they need someone in seat. Our Clinical Development and Clinical Operations teams are seeing the same pressure.




How to compete for scarce commercial talent in 2027

  1. Start early. If you plan to hire in Q1, start the search now. The best people will have options by January.
  2. Be clear on the role. For BD especially, define whether you need a hunter or a farmer, and which markets they must know.
  3. Benchmark pay realistically. Companies are paying above market for these roles. If your offer sits at the midpoint, expect to lose candidates late in the process.
  4. Move quickly. Long interview processes cost you the strongest candidates. Agree your stages and decision-makers before you start.
  5. Sell the story. Candidates want to know about your funding, pipeline and growth plans. Make that part of the pitch.
  6. Use a specialist. A permanent recruitment partner with a live network in your market can reach people who aren't actively looking. Our case studies show how that works in practice.




For candidates

If you work in BD, commercial analysis or as a PI, 2027 looks like a strong year to make a move. Companies are planning early and are prepared to pay for the right person. If you'd like a confidential conversation about what's out there, get in touch.




Frequently asked questions

Which life sciences roles are most in demand for 2027? 

Business development, Business Analysts and principal investigators were the roles that came up most across CDMOs, CROs and biotech companies.

Why are companies paying above market for commercial talent? 

Demand for the right people is outpacing supply, so companies are paying a premium to secure experienced hires quickly.

Why is there demand for PIs in Australia? 

Australia is emerging as a destination for early-phase work in the CRO and CRDMO space, which is driving demand for PI hires there and in parts of Europe.

Why are Asian and Indian companies hiring BD teams in Europe? 

Many are acquiring European entities to gain local infrastructure and approved products, and they need local BD teams to sell them.




Talk to us

Planning to grow your commercial team in 2027? Speak to Austin and our commercial recruitment team, or contact us to start the conversation. You can also meet the team, read more market insights on our blog or listen to our podcasts.